Expanding Therapeutic Possibilities Pursuing pMHC Targets Beyond Convention

• Antigen-guided TCE development
• Targeting haptenated peptides as a way of breaking HLA restriction
• Exploiting resistance mechanisms to cancer treatments that unlock new targets for immunotherapies

New Data

Speakers:

Lorenzo Maso

Principal Scientist

Aethon Therapeutics